158 related articles for article (PubMed ID: 28870123)
1. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms.
Thall PF; Ursino M; Baudouin V; Alberti C; Zohar S
Stat Methods Med Res; 2019 Feb; 28(2):404-418. PubMed ID: 28870123
[TBL] [Abstract][Full Text] [Related]
2. Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.
Hampson LV; Whitehead J; Eleftheriou D; Tudur-Smith C; Jones R; Jayne D; Hickey H; Beresford MW; Bracaglia C; Caldas A; Cimaz R; Dehoorne J; Dolezalova P; Friswell M; Jelusic M; Marks SD; Martin N; McMahon AM; Peitz J; van Royen-Kerkhof A; Soylemezoglu O; Brogan PA
PLoS One; 2015; 10(3):e0120981. PubMed ID: 25822991
[TBL] [Abstract][Full Text] [Related]
3. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM; Wong SC; Willis NS; Craig JC
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.
Zhao W; Elie V; Baudouin V; Bensman A; André JL; Brochard K; Broux F; Cailliez M; Loirat C; Jacqz-Aigrain E
Br J Clin Pharmacol; 2010 Apr; 69(4):358-66. PubMed ID: 20406220
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.
Baudouin V; Alberti C; Lapeyraque AL; Bensman A; André JL; Broux F; Cailliez M; Decramer S; Niaudet P; Deschênes G; Jacqz-Aigrain E; Loirat C
Pediatr Nephrol; 2012 Mar; 27(3):389-96. PubMed ID: 21947272
[TBL] [Abstract][Full Text] [Related]
6. Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil
Ehren R; Benz MR; Doetsch J; Fichtner A; Gellermann J; Haffner D; Höcker B; Hoyer PF; Kästner B; Kemper MJ; Konrad M; Luntz S; Querfeld U; Sander A; Toenshoff B; Weber LT;
BMJ Open; 2018 Oct; 8(10):e024882. PubMed ID: 30309995
[TBL] [Abstract][Full Text] [Related]
7. Bayesian methods for the design and interpretation of clinical trials in very rare diseases.
Hampson LV; Whitehead J; Eleftheriou D; Brogan P
Stat Med; 2014 Oct; 33(24):4186-201. PubMed ID: 24957522
[TBL] [Abstract][Full Text] [Related]
8. [Immunity and immunosuppression in childhood idiopathic nephrotic syndrome].
Frange P; Frey MA; Deschênes G
Arch Pediatr; 2005 Mar; 12(3):305-15. PubMed ID: 15734130
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study.
Mekahli D; Liutkus A; Ranchin B; Yu A; Bessenay L; Girardin E; Van Damme-Lombaerts R; Palcoux JB; Cachat F; Lavocat MP; Bourdat-Michel G; Nobili F; Cochat P
Pediatr Nephrol; 2009 Aug; 24(8):1525-32. PubMed ID: 19280229
[TBL] [Abstract][Full Text] [Related]
10. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
Wu B; Mao J; Shen H; Fu H; Wang J; Liu A; Gu W; Shu Q; Du L
Nephrology (Carlton); 2015 Jan; 20(1):18-24. PubMed ID: 25312783
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian non-inferiority approach using experts' margin elicitation - application to the monitoring of safety events.
Aupiais C; Alberti C; Schmitz T; Baud O; Ursino M; Zohar S
BMC Med Res Methodol; 2019 Sep; 19(1):187. PubMed ID: 31533631
[TBL] [Abstract][Full Text] [Related]
12. Remote, real-time expert elicitation to determine the prior probability distribution for Bayesian sample size determination in international randomised controlled trials: Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone (BIPED) study.
Lan J; Plint AC; Dalziel SR; Klassen TP; Offringa M; Heath A;
Trials; 2022 Apr; 23(1):279. PubMed ID: 35410375
[TBL] [Abstract][Full Text] [Related]
13. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.
Saint-Marcoux F; Guigonis V; Decramer S; Gandia P; Ranchin B; Parant F; Bessenay L; Libert F; Harambat J; Bouchet S; Broux F; Compagnon P; Marquet P
Pharmacol Res; 2011 May; 63(5):423-31. PubMed ID: 21272643
[TBL] [Abstract][Full Text] [Related]
14. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
[TBL] [Abstract][Full Text] [Related]
15. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM; Habashy D; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD003594. PubMed ID: 16625586
[TBL] [Abstract][Full Text] [Related]
16. Therapy: Maintenance of steroid-free remission in nephrotic syndrome.
Deegens JK; Wetzels JF
Nat Rev Nephrol; 2015 Oct; 11(10):569-70. PubMed ID: 26195145
[No Abstract] [Full Text] [Related]
17. Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies.
Jiang X; Shen W; Xu X; Shen X; Li Y; He Q
Clin Exp Nephrol; 2018 Jun; 22(3):562-569. PubMed ID: 29080118
[TBL] [Abstract][Full Text] [Related]
18. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM; Willis NS; Craig JC
Cochrane Database Syst Rev; 2010 Nov; (11):CD003594. PubMed ID: 21069676
[TBL] [Abstract][Full Text] [Related]
19. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Habashy D; Hodson E; Craig J
Cochrane Database Syst Rev; 2004; (2):CD003594. PubMed ID: 15106208
[TBL] [Abstract][Full Text] [Related]
20. Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches.
Smania G; Baiardi P; Ceci A; Cella M; Magni P
CPT Pharmacometrics Syst Pharmacol; 2016 Aug; 5(8):402-10. PubMed ID: 27530374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
